December 9, 2020 10:47 AM EST
R&D
Pharma

No­var­tis' CDK4/6 med Kisqali, firm­ly the sales un­der­dog against Pfiz­er's Ibrance, drops big OS da­ta

Kyle Blankenship

With block­buster Ibrance from Pfiz­er in its sights, No­var­tis push­ing hard to build the clin­i­cal case for CDK4/6 in­hibitor Kisqali with three years on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times